Status: Not yet recruiting
CAR-T Cell Efficacy With Molecular Imaging in Multiple Myeloma
⁶⁸Ga-NOTA-BCMA is a novel, targeted PET tracer under clinical investigation. It is designed to provide a non-invasive method for monitoring the biodistribution and persistence of BCMA CAR-T cells in patients. Preclinical data robustly support its specific binding, favorable pharmacokinetics, and excellent safety profile, warranting its advancement into clinical studies.
Participants needed: 10
Trial details
Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Xuzhou Medical UniversityUpdated: Dec 17, 2025
Eligibility criteria
**Inclusion Criteria** [+6]
**Exclusion Criteria** [+8]